Trommelen J, van Lieshout G, Pabla P, et al
Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Current FDA labeling for semaglutide products includes warnings or precautions involving: Acute pancreatitis Acute gallbladder disease Acute kidney injury due to volume depletion Severe gastrointestinal reactions Hypoglycemia when combined with insulin or insulin secretagogues Diabetic retinopathy complications in susceptible patients Serious hypersensitivity reactions Pulmonary aspiration risk during general anesthesia or deep sedation Semaglutide labeling also contains a boxed warning regarding thyroid C-cell tumors observed in rodents
In the coming months, the OVBHCD will expand its analysis of pharmacy spending to include all medications, offering further context to pharmacy spending among the commercial, fully insured population
Flexible Medication Options: Patients can choose injectable or oral GLP-1 options, allowing treatment to fit personal preferences and lifestyles
Oral Tirzepatide: An oral option for tirzepatide, if appropriate for your needs
